We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
SkyePharma has struck a long-awaited partnership deal for its biggest drug hope,
saying U.S. group Kos Pharmaceuticals will help develop and market Flutiform
for asthma in the United States.
